For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Altimmune, Inc. (ALT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Altimmune, Inc. is one of 1180 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Altimmune, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ALT's full-year earnings has moved 19.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ALT has returned 28.5% so far this year. At the same time, Medical stocks have lost an average of 14.6%. This shows that Altimmune, Inc. is outperforming its peers so far this year.
Chinook Therapeutics is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 10.4%.
For Chinook Therapeutics, the consensus EPS estimate for the current year has increased 17.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Altimmune, Inc. belongs to the Medical - Drugs industry, which includes 231 individual stocks and currently sits at #142 in the Zacks Industry Rank. Stocks in this group have lost about 21.4% so far this year, so ALT is performing better this group in terms of year-to-date returns. Chinook Therapeutics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Altimmune, Inc. and Chinook Therapeutics as they could maintain their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Altimmune, Inc. (ALT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Altimmune, Inc. is one of 1180 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Altimmune, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ALT's full-year earnings has moved 19.9% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, ALT has returned 28.5% so far this year. At the same time, Medical stocks have lost an average of 14.6%. This shows that Altimmune, Inc. is outperforming its peers so far this year.
Chinook Therapeutics is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 10.4%.
For Chinook Therapeutics, the consensus EPS estimate for the current year has increased 17.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Altimmune, Inc. belongs to the Medical - Drugs industry, which includes 231 individual stocks and currently sits at #142 in the Zacks Industry Rank. Stocks in this group have lost about 21.4% so far this year, so ALT is performing better this group in terms of year-to-date returns. Chinook Therapeutics is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to Altimmune, Inc. and Chinook Therapeutics as they could maintain their solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ALT - FREE